Literature DB >> 25864940

Treatment of paroxysmal dyskinesias in children.

Jonathan W Mink1.   

Abstract

OPINION STATEMENT: Paroxysmal dyskinesia represents a group of uncommon movement disorders that are characterized by episodes of abnormal movements arising from a baseline of normal or nearly normal movement. Recent advances in the genetics of these disorders have helped provide some unification of classification schemes and better understanding. However, the approach to treatment continues to be based on the phenotype more than the genotype. The treatment approach is primarily based on the factors that precipitate the episodes of abnormal movements. For paroxysmal kinesigenic dyskinesia (PKD) in which the spells are triggered by sudden movement, treatment with anticonvulsants that target voltage-sensitive sodium channels (e.g., carbamazepine or phenytoin) is highly effective. For paroxysmal nonkinesigenic dyskinesia (PNKD), treatment with benzodiazepines is effective in many patients. PNKD episodes are often precipitated by caffeine, ethanol, or sleep deprivation, and lifestyle modifications are often helpful. Paroxysmal exertion-induced dyskinesia (PED) is less likely to respond to medications, but the ketogenic diet or modified Atkins diet may provide benefit. As more knowledge is gained about the underlying biology of these disorders, additional treatments may emerge.

Entities:  

Year:  2015        PMID: 25864940     DOI: 10.1007/s11940-015-0350-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  47 in total

1.  PAROXYSMAL CHOREOATHETOSIS. ASSOCIATED WITH PERINATAL HYPOXIC ENCEPHALOPATHY.

Authors:  J A ROSEN
Journal:  Arch Neurol       Date:  1964-10

2.  Familial paroxysmal dystonia induced by exercise.

Authors:  G T Plant; A C Williams; C J Earl; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-03       Impact factor: 10.154

3.  Long-term clinical course of Glut1 deficiency syndrome.

Authors:  Aliza S Alter; Kristin Engelstad; Veronica J Hinton; Jacqueline Montes; Toni S Pearson; Cigdem I Akman; Darryl C De Vivo
Journal:  J Child Neurol       Date:  2014-04-30       Impact factor: 1.987

4.  Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied.

Authors:  A Kertesz
Journal:  Neurology       Date:  1967-07       Impact factor: 9.910

5.  Topiramate therapy for paroxysmal kinesigenic choreoathetosis.

Authors:  Yuan-Gui Huang; Yun-Chun Chen; Fang Du; Rui Li; Ge-Lin Xu; Wen Jiang; Jing Huang
Journal:  Mov Disord       Date:  2005-01       Impact factor: 10.338

6.  Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis.

Authors:  Shirley Rainier; Donald Thomas; Debra Tokarz; Lei Ming; Melanie Bui; Erin Plein; Xinping Zhao; Rosemary Lemons; Roger Albin; Colin Delaney; David Alvarado; John K Fink
Journal:  Arch Neurol       Date:  2004-07

7.  Paroxysmal dystonia as the initial manifestation of multiple sclerosis.

Authors:  J R Berger; W A Sheremata; E Melamed
Journal:  Arch Neurol       Date:  1984-07

8.  Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis.

Authors:  Anjan Chatterjee; Elan D Louis; Steven Frucht
Journal:  Mov Disord       Date:  2002-05       Impact factor: 10.338

9.  Phenytoin plasma concentrations in paroxysmal kinesigenic choreoathetosis.

Authors:  R W Homan; M R Vasko; M Blaw
Journal:  Neurology       Date:  1980-06       Impact factor: 9.910

10.  Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations.

Authors:  Laura Silveira-Moriyama; Alice R Gardiner; Esther Meyer; Mary D King; Martin Smith; Karl Rakshi; Alasdair Parker; Andrew A Mallick; Richard Brown; Grace Vassallo; Philip E Jardine; Marilisa M Guerreiro; Andrew J Lees; Henry Houlden; Manju A Kurian
Journal:  Dev Med Child Neurol       Date:  2013-01-30       Impact factor: 5.449

View more
  4 in total

1.  Genetics of Paroxysmal Dyskinesia: Novel Variants Corroborate the Role of KCNA1 in Paroxysmal Dyskinesia and Highlight the Diverse Phenotypic Spectrum of KCNA1- and SLC2A1-Related Disorders.

Authors:  Josua Kegele; Johanna Krüger; Mahmoud Koko; Lara Lange; Ana Victoria Marco Hernandez; Francisco Martinez; Alexander Münchau; Holger Lerche; Stephan Lauxmann
Journal:  Front Neurol       Date:  2021-07-08       Impact factor: 4.003

Review 2.  Medical treatment of dystonia.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2016-12-19

3.  Clinical features of patients with paroxysmal kinesigenic dyskinesia, mutation screening of PRRT2 and the effects of morning draughts of oxcarbazepine.

Authors:  Gang Pan; Linmei Zhang; Shuizhen Zhou
Journal:  BMC Pediatr       Date:  2019-11-14       Impact factor: 2.125

4.  Presynaptic PRRT2 Deficiency Causes Cerebellar Dysfunction and Paroxysmal Kinesigenic Dyskinesia.

Authors:  Dylan J Calame; Jianfeng Xiao; Mohammad Moshahid Khan; T J Hollingsworth; Yi Xue; Abigail L Person; Mark S LeDoux
Journal:  Neuroscience       Date:  2020-09-04       Impact factor: 3.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.